ArQule up on hope for lung cancer drug revival

(Reuters) - ArQule Inc shares jumped 19 percent on hopes that additional data from a discontinued trial could revive its experimental drug, tivantinib, as a treatment for lung cancer. Last October, ArQule and Daiichi Sankyo Inc stopped a late-stage trial of tivantinib to treat lung cancer after determining that the drug did not improve patient survival. ArQule is expected to present additional data from the trial at the European Society of Medical Oncology (ESMO) conference in Amsterdam, according to RBC Capital Markets analyst Adnan Butt. ...



via Health News Headlines - Yahoo! News http://news.yahoo.com/arqule-hope-lung-cancer-drug-revival-153843991--finance.html